Abstract Autophagy is a catabolic process that degrades long-lived proteins and damaged organelles by sequestering them into double membrane structures termed ''autophagosomes'' and fusing them with lysosomes. Autophagy is active in the heart at baseline and further stimulated under stress conditions including starvation, ischemia/ reperfusion, and heart failure. It plays an adaptive role in the heart at baseline, thereby maintaining cardiac structure and function and inhibiting age-related cardiac abnormalities. Autophagy is activated by ischemia and nutrient starvation in the heart through Sirt1-FoxO-and adenosine monophosphate (AMP)-activated protein kinase (AMPK)-dependent mechanisms, respectively. Activation of autophagy during ischemia is essential for cell survival and maintenance of cardiac function. Autophagy is strongly activated in the heart during reperfusion after ischemia. Activation of autophagy during reperfusion could be either protective or detrimental, depending on the experimental model. However, strong induction of autophagy accompanied by robust upregulation of Beclin1 could cause autophagic cell death, thereby proving to be detrimental. This review provides an overview regarding both protective and detrimental functions of autophagy in the heart and discusses possible applications of current knowledge to the treatment of heart disease.
Autophagy is a catabolic process whereby long-lived proteins in the cytosol and organelles are sequestered into double-membrane vesicles termed autophagosomes and transported to lysosomes for degradation [10, 14, 19] . Autophagy occurs in basal conditions and mediates homeostatic functions in cells. However, autophagy also is induced by stress such as nutrient starvation, hypoxia, endoplasmic reticulum stress, and oxidative stress [19] .
During nutrient starvation, autophagy allows cells to recycle extracted amino acids and fatty acids for adenosine triphosphate (ATP) production via the tricarboxylic acid (TCA) cycle. Autophagosomes sequester damaged organelles such as mitochondria, endoplasmic reticulum, and ribosomes for degradation, thereby preventing release of reactive oxygen species (ROS) and inducers of cell death [10, 14, 19] .
Autophagy also can induce cell death in some conditions. This form of cell death is referred to as type 2 programmed cell death but may simply be caused by excessive activation of autophagy. For example, strong autophagy promotes depletion of essential proteins and organelles and is therefore potentially harmful for cells [19] .
Autophagy is easily detected under basal conditions in the heart, but it is further enhanced during fasting and other pathologic conditions including cardiac remodeling, heart failure, and ischemia/reperfusion [22, 32] . The functional significance of autophagy in the heart during stress is complex. Whether autophagy is salutary or detrimental is context dependent. In general, a modest increase in autophagy under stress conditions appears to be protective, whereas massive activation may be detrimental in the heart. The nature of the stress triggering autophagy and the underlying signaling mechanism also appear to affect the functional significance of autophagy in the heart [17, 21, 22] . This review discusses both the protective and detrimental functions of autophagy in the heart at baseline and in response to myocardial ischemia and reperfusion.
Autophagy Machinery and Signaling
Autophagy occurs in at least three distinct forms: (1) microautophagy, in which lysosomes directly engulf cytosolic constituents through invagination of lysosomal membranes; (2) chaperone-mediated autophagy, in which specific proteins are delivered to lysosomes through their binding to the chaperone, heat shock cognate 70; and (3) macroautophagy, characterized by the formation of doublemembrane vesicles termed autophagosomes, which sequester macromolecules and finally fuse with lysosomes, wherein the contents are digested. In this review, we limit our discussion to macroautophagy, hereafter referred to as ''autophagy.''
The autophagic process consists of four stages: induction, nucleation, expansion, and maturation/retrieval of autophagosomes [10, 14] . Induction and nucleation include the formation of an isolation membrane known as a phagophore from a source site, which could be the endoplasmic reticulum, the mitochondria, or some other unknown source [1, 10, 14] . Phagophores localize to the phagophore assembly site, where constituents of the autophagy machinery are recruited; expand to engulf cytosolic constituents (cargo); and develop into autophagosomes. Autophagosomes then are transported through their binding to cytoskeletal constituents, such as microtubules, and finally are directed to lysosomes for fusion.
Autophagosome formation is regulated by the autophagy-related genes (ATG) [10, 14] . Genetic screenings in yeast have identified more than 30 ATGs, most of which have mammalian homologs. Phagophore induction and expansion are induced mainly by the class 3 phosphoinositide 3-kinase, Vps34, which forms a multiprotein complex with Beclin1, Atg14 and Vps150, leading to the formation of phosphatidylinositol 3-phosphate (PtdIns3P). The latter is required for recruitment of other regulatory proteins at the phagophore assembly site, allowing expansion of the phagophore.
Phagophore induction also is triggered by a macromolecular complex formed by Atg13, Unc-51-like kinase 1 (Ulk1, a homologue of the yeast Atg1), and Ulk2, which phosphorylates the focal adhesion kinase family interacting protein 200 (FIP200), promoting initiation of autophagy [10, 14] . The elongation phase of the phagophore is regulated by two ubiquitination-like reactions. First, Atg12 is conjugated to Atg5 in a reaction catalyzed by Atg7 and Atg10. The Atg12-Atg5 complex binds to the phagophore membrane and promotes its elongation. Subsequently, Atg7, Atg3, and the Atg12-Atg5 complex modulate the conjugation of the cytosolic form of LC3 (Atg8) known as LC3-I to phosphatidylethanolamine to form a membraneassociated form of LC3 known as LC3-II, which is crucial for autophagosome expansion. It induces membrane tethering and hemifusion and controls the size of the autophagosome by regulating the membrane curvature.
Once the autophagosome formation is completed, LC3-II is released to the cytosol after its Atg4-mediated cleavage from phosphatidylethanolamine [10, 14] . The molecular mechanism and genes involved in the autophagosome fusion to lysosomes in mammals still are unclear, although it is known that such an event requires a lysosome membrane protein, LAMP-2, and a small GTPase, Rab7. It is recognized that Soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) proteins are crucial for autophagosome fusion to vacuoles in yeast [10, 14] .
Autophagy in the Heart Under Basal Conditions and During Aging
Autophagy is essential to the maintenance of cardiomyocyte (CM) structure and function. Cardiac-specific deletion of atg5 in adult mice rapidly induces cardiac hypertrophy, left ventricular dilation, and contractile dysfunction, which is accompanied by increases in protein ubiquitination/ aggregation, endoplasmic reticulum stress, disorganized sarcomere structure, and mitochondrial misalignment [20] . In humans, Danon's disease is caused by a deficiency of lysosomal membrane glycoprotein-2 (LAMP-2), in which the loss of function in LAMP-2 causes impairment of autophagosome-lysosome fusion [25] . As a consequence, the content of autophagosomes cannot be degraded properly. Danon's disease is characterized by mental retardation, myopathy, and a severe cardiomyopathy with left ventricle dilation and dysfunction [22, 25] . Autophagy also is required for maintenance of cardiac function during aging. Although cardiac autophagy is downregulated during aging, further deletion of atg5 in the mouse heart during aging facilitates cardiac dysfunction and aging cardiomyopathy [30] . Taken together, these results suggest that a certain level of autophagy is required to maintain normal structure and function in the heart.
Autophagy During Myocardial Ischemia
Autophagy is stimulated during hypoxia or ischemia in the heart and the CMs therein [22] . During hypoxia/ischemia, the energy reserve in the heart is rapidly depleted, together with decreases in the cellular ATP content. Activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), which acts as a sensor for energy deprivation, mediates metabolic adaptation during hypoxia/ischemia. Because inhibition of AMPK significantly suppresses autophagy during myocardial ischemia, activation of AMPK is required for induction of autophagy [16] .
Activation of AMPK not only inhibits the mammalian target of rapamycin (mTOR) through phosphorylation of tuberous sclerosis complex 2 (TSC2) but also induces phosphorylation of eukaryotic elongation factor 2 (eEF2). Inhibition of mTOR and phosphorylation of eEF2 inhibit protein synthesis, an energy consuming process, and stimulate autophagy, both of which contribute to hypoxic adaptation [17] .
The relative importance of mTOR inhibition and eEF2 phosphorylation in mediating AMPK-induced autophagy is unknown. We have shown recently that mTOR also is inhibited during ischemia in the heart through dephosphorylation/activation of glycogen synthase kinase-3b (GSK-3b) [34] . The molecular mechanism through which myocardial ischemia inhibits the activity of mTOR also requires further clarification.
Besides these signaling mechanisms involving mTOR, stimulation of autophagy may be promoted by upregulation of hypoxia-inducible factor-1 (HIF-1) during hypoxia/ ischemia [2, 35] . The relative contributions of mTOR inhibition and HIF-1 upregulation to the induction of autophagy during myocardial hypoxia/ischemia are currently unknown.
Studies conducted to date support the notion that autophagy generally is protective during myocardial ischemia. Autophagy may compensate for the loss of energy by regeneration of amino acids and fatty acids, which can be used for ATP synthesis through the TCA cycle. Obviously, however, ATP cannot be made through the TCA cycle when aerobic respiration is completely shut down during severe or prolonged ischemia.
In addition, because some processes in autophagy, such as autophagosome formation, are ATP dependent, autophagy itself and the consequent production of ATP cannot take place under complete ischemia. Alternatively, autophagy removes damaged mitochondria, thereby reducing ROS and inhibiting the release of pro-apoptotic factors such as cytochrome c. Finally, autophagy may scavenge protein aggregates, which accumulate during ischemia [15, 17, 19] .
Yan et al. [33] demonstrated that autophagy is significantly upregulated during chronic ischemia (i.e., myocardial hibernation) in the pig heart. In this model, the level of autophagy inversely correlated with that of apoptosis in the ischemic area. The ischemic area was recovered with little cell death when the coronary flow was restored, suggesting that autophagy may protect the myocardium from apoptosis during hibernation [33] . Inhibition of endogenous AMPK suppressed autophagy during prolonged ischemia, which was accompanied by enlargement of the myocardial infarction [28] .
Because these studies demonstrate correlation only between autophagy and cardioprotection during ischemia, the causative role of autophagy in mediating protection against chronic or prolonged ischemia remains to be demonstrated. If stimulation of autophagy during ischemia is truly protective, interventions to enhance autophagy should be protective during myocardial ischemia.
Currently, an intervention that selectively induces autophagy remains to be developed. Even if such an intervention were available, however, it would be difficult to treat the heart with the drug in the absence of perfusion. Recent evidence suggests, however, that autophagy is induced by ischemic preconditioning [6, 11] . Thus, activation of autophagy through pharmacologic preconditioning may reduce myocardial injury during prolonged ischemia. In addition, as discussed later, excessive activation of autophagy during reperfusion is potentially harmful. If this hypothesis is true, interventions to augment autophagy should be given only before or during ischemia but should not be extended to the reperfusion period.
Autophagy is progressively activated in mice after 3 days of fasting, which is paralleled by a progressive decline in the heart weight [12, 29] . This is another example in which autophagy is activated by energy starvation in the heart. Although normal mice maintain cardiac function during fasting, inhibition of autophagy leads to the rapid development of cardiac dysfunction, suggesting that autophagy plays a critical role in maintaining cardiac function during nutrient starvation [9] .
Autophagy is critical for maintaining cardiac function immediately after birth, when newborn mice suffer from nutrient starvation until they establish nutrition from breastfeeding [13] . We have shown recently that fasting activates FoxO through Sirt1-mediated deacetylation, which in turn induces expression of Rab7, thereby stimulating autophagosome-lysosome fusion. Downregulation of FoxO1 or suppression of FoxO1 deacetylation inhibits starvation-induced autophagy and promotes cardiac dysfunction during fasting [9] . These results suggest that starvation-induced autophagy activated through the Sirt1-FoxO-dependent mechanism is adaptive for the heart and the CMs therein.
Autophagy During Myocardial Reperfusion
Although various interventions during the acute phase of myocardial infarction aim at restoring coronary flow and supply oxygen and nutrients to ischemic myocardium, reperfusion itself leads to further heart damage, termed Pediatr Cardiol (2011) 32:275-281 277 ''reperfusion injury.'' Although it may be speculated that activation of autophagy may be reversed as soon as ischemia is relieved, the level of autophagy in fact further increases during reperfusion [16] . Mechanisms mediating autophagy during reperfusion appear to be different from those involved in autophagy during ischemia. An energy crisis in the heart, a major stimulus for autophagy, is at least partially resolved at the time of reperfusion. Instead, ROS appear to be a major promoter of autophagy during reperfusion, inducing mitochondrial damage/dysfunction, as evidenced by mitochondrial permeability transition pore (mPTP) opening and mitochondrial fragmentation. This in turn promotes autophagy and/or mitophagy, a specialized form of autophagy that removes mitochondria [4] . Findings show that ROS oxidize and inhibits the cysteine protease activity of Atg4, which results in LC3 lipidation and autophagy [27] . We have shown recently that ROS play an important role in mediating the upregulation of Beclin1 and the stimulation of autophagy in the mouse heart during ischemia/reperfusion [9] . Because Beclin1 is strongly upregulated during the reperfusion phase but not during the ischemia phase, strong induction of Beclin1 by ROS may play an important role in mediating stimulation of autophagy during reperfusion. Angiotensin 2 (Ang 2) receptor signaling also may play a role in stimulating autophagy in response to ischemia/reperfusion.
In a recent study, Porrello et al. [24] found that Ang 2 treatment in the presence of adenovirus-mediated Ang 2 type 1 receptor (AT1R) overexpression caused a marked autophagy increase in cultured neonatal rat CMs. In contrast, Ang 2 type 2 receptor (AT2R) overexpression inhibited autophagy in an Ang 2-independent manner. Neonatal CMs cultured from hypertrophic rat hearts were more susceptible to AT1R-stimulated autophagy than CMs from normal rat hearts, and there was a significantly greater increase in autophagic marker upregulation in adult hypertrophic rat hearts than in normal rat hearts after ex vivo ischemia/reperfusion. Thus, Ang 2/AT1R signaling may be involved in the stimulation of autophagy by ischemia/reperfusion.
Whether autophagy induced during reperfusion is beneficial or detrimental remains controversial. HamacherBrady et al. [7] have shown that although autophagic flux is inhibited during ischemia/reperfusion, enhancing autophagic flux during ischemia/reperfusion protects against ischemia/reperfusion injury in CMs in vitro. In contrast, Valentim et al. [31] have shown that inhibiting autophagy by treatment with 3-methyladenine or by Beclin1 knockdown increases the survival of CMs after ischemia/reperfusion in vitro.
Our group has shown that autophagosome formation and the size of myocardial infarction are significantly attenuated in beclin1-positive and -negative mice subjected to ischemia/reperfusion, suggesting that upregulation of autophagy is detrimental during ischemia/reperfusion [16] . Beclin1 regulates both autophagosome formation and autophagic flux by interacting with rubicon, which inhibits autophagic flux [18, 36] . Whether beclin1-positive andnegative mice show decreases in autophagosomes during ischemia/reperfusion due to decreases in autophagy formation or increases in autophagic flux (aided by the absence of rubicon breakdown) has been raised as a point of debate [5] .
Using tandem fluorescent LC3 indicator mice, we have shown recently that ischemia/reperfusion increases both autophagosome and autolysosome formation in vivo, indicating that autophagic flux is increased during ischemia/reperfusion [9] . In this study, 2-mercaptopropionyl glycine, an antioxidant, protected against ischemia/reperfusion injury, which was accompanied by suppression of autophagic flux, suggesting that suppressing autophagic flux may be protective during ischemia/reperfusion [9] . More recently, we have found that suppression of autophagy by downregulation of Ulk1, another mediator of autophagy, inhibits the size of myocardial infarction in response to ischemia/reperfusion (not shown), consistent with the notion that the protective effect of Beclin1 and Ulk1 downregulation during ischemia/reperfusion is mediated through suppression of autophagy.
Molecular mechanisms mediating the detrimental effects of autophagy during reperfusion are not completely understood. Due to the relatively nonspecific nature of its degradation, autophagy may digest organelles and proteins that could protect CMs from cell death during reperfusion. For example, autophagy degrades catalase, a critical enzyme-reducing H 2 O 2 [26] , which may in turn lead to increases in oxidative stress and apoptosis. It remains to be elucidated why autophagy can be protective during reperfusion under some experimental conditions.
A direct correlation exists between the severity of ischemia and the extent of autophagy during the reperfusion phase [3] . If ischemia is mild, activation of autophagy during reperfusion may be modest and thus may not be harmful. In addition, inhibiting autophagy at the level of autophagosome formation and at the level of autophagosome-lysosome fusion may differentially affect ischemia/ reperfusion injury.
Perspectives
Judging from the intimate involvement of autophagy in pathophysiology of the heart, modulation of autophagy could significantly affect the function of the heart in patients with heart disease. To translate our knowledge of autophagy into treatment of heart disease, it would be important to know more precisely when autophagy is protective and when it is detrimental for the heart (Fig. 1 ).
An important caveat in studies of autophagy with experimental animals is the fact that many interventions to inhibit autophagy affect autophagy-independent mechanisms as well. Thus, ideally, the function of autophagy during stress in the heart should be evaluated using animal models with multiple loss of function.
Another important issue in the study of autophagy in the heart is to elucidate the upstream signaling mechanisms positively and negatively regulating autophagy in the heart. Currently, the molecular mechanisms mediating adaptive and maladaptive autophagy are not well understood. We have proposed that autophagy mediated by either AMPK- [16] or Sirt1-FoxO-dependent signaling mechanisms [8] may be protective, whereas that caused by robust upregulation of Beclin1 due to oxidative stress could be detrimental for the heart [9, 16] . Further studies are required to test whether this hypothesis can be extended to autophagy in the human heart in various clinical settings.
Recent evidence suggests that autophagy could be mediated by both Atg5/Atg7-dependent and Atg5/Atg7-independent (Rab9-dependent) mechanisms [23] . Thus, it is possible that distinct forms of autophagy may exist and that some forms of autophagy could be beneficial whereas other forms of autophagy are detrimental.
Finally, it would be important to develop small molecule compounds that can either stimulate or inhibit autophagy in the heart. Such compounds would allow adjustment of the autophagy level in the heart to physiologic levels during aging as well as either stimulation or inhibition of autophagy during ischemia and reperfusion to maintain energy status, protein quality control, and organelle function under better conditions.
In addition, autophagy may be stimulated to compensate for the function of the ubiquitin proteasome, remove protein aggregates, and achieve better protein quality control in some conditions, such as aging and cardiomyopathy. Modulation of autophagy is expected to add unique benefits in addition to those of conventional therapies for heart disease. Thus, further investigation into the role of autophagy in human heart disease should provide us with promising outcomes.
